Le Lézard
Classified in: Health, Science and technology
Subjects: PARTNERSHIPS, LICENSING AGREEMENTS

Radient Technologies Announces partnership with US based Dreamy CBD


EDMONTON, Alberta, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Radient Technologies Inc. ("Radient" or the "Company") (TSX Venture: RTI; OTCQX: RDDTF), is pleased to announce a licensing agreement with Dreamy Co., ("Dreamy") to bring in Dreamy CBD products under Radient's platform to Canada and extend it to other international markets. Initially founded in the US, Dreamy has developed a lifestyle brand over the past decade focused on the Health and Wellness space before branching into the CBD vertical. Dreamy is focused on creating and inspiring people to use plant medicine and holistic healing in place of conventional pharmaceutical solutions. In the US, Dreamy CBD enjoys a strong presence in California, and the Dreamy brand has a strong association with a positive lifestyle in the rapidly growing Wellness space. The Dreamy CBD products comprise CBD tinctures, CBD distillates, CBD edibles, CBD cosmetics, and CBD Vape Cartridges geared towards the recreational and medical cannabis market.

Under this partnership, Radient will have exclusive rights to the licenses and trademarks for Dreamy CBD brands and will collaborate jointly with Dreamy to produce their CBD products and launch their brands in Canada. Radient will be involved in providing the processing facilities in Edmonton and the necessary infrastructure to extract CBD products for Dreamy CBD. In addition, through its Sales License and associated registrations in the provinces, Radient will look to build the Dreamy CBD product portfolio in Canada. On the international front, Radient will produce their CBD based products for markets in Thailand and Japan that are witnessing a strong surge in CBD products consumption, especially in the Wellness space. This will be after completing a comprehensive review of the trade requirements with local partners in these jurisdictions. The partnership is being set initially for a two-year term with an annual renewable option, with Radient reserving the right of first refusal to acquire Dreamy.

About Radient 

Radient Technologies is an innovative science-based company that is a commercial manufacturer of high quality cannabinoid based formulations, ingredients and products. Utilizing a proprietary extraction and downstream processing platform that recovers up to 99% of cannabinoids from the cannabis plant, Radient develops specialty products and ingredients that contain a broad range of cannabinoid and terpene profiles while meeting the highest standards of quality and safety. Radient also has a science lab that is focused on innovation with expertise in formulations and technologies offering unique solutions in the cannabis and wellness space. Please visit www.radientinc.com for more information.

SOURCE: Radient Technologies Inc.

For further information please contact:

Radient - Investor Relations, [email protected]

Forward Looking Information:
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the growth of the Company's business operations. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Radient, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although Radient has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Radient does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.



These press releases may also interest you

at 03:00
Todd Britten, DMD, a board-certified periodontist and dental implant specialist in...

at 03:00
SK chemicals (CEO Ahn Jae-hyun), Dongsung Chemical (Co-CEOs Baek Jin-woo and Lee Man-woo), and BYN Black Yak (Chairman Kang Tae-sun, hereinafter Black Yak) announced on the 18th that they've developed sustainable footwear materials using the...

at 02:55
First quarter  Sales of SEK 841 (854) million, a flat growth in local currencies and a decrease of 2% in SEK.Sales per region, in local currencies was +19% in APAC, -2% in EMEA and -14% in Americas.Sales per business area, in local currencies was...

at 02:05
PureTech Health plc ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December 31, 2023, on Thursday, April 25, 2024. A presentation and conference call to discuss the results...

at 02:05
Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and year-end report for January to March 2024. Highlights for the first quarter of 2024      Strong commercial...

at 01:30
The shares in Aker ASA will be traded ex-dividend NOK 15.50 as from today, 18 April 2024. Investor contact:Fredrik Berge, Head of Investor Relations Aker ASA Tel: +47 450 32 090 E-mail: [email protected] Media contact:Atle Kigen, Head of...



News published on and distributed by: